Skip to main content
Erschienen in: Clinical & Experimental Metastasis 8/2016

07.09.2016 | Research Paper

Impact of disease free status on prognosis in metastatic non-small round cell soft tissue sarcomas

verfasst von: Hiroshi Urakawa, Eiji Kozawa, Kunihiro Ikuta, Shunsuke Hamada, Naoki Ishiguro, Yoshihiro Nishida

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 8/2016

Einloggen, um Zugang zu erhalten

Abstract

The aim of this study is to examine the impact of disease free (DF) status on the prognosis in patients with metastatic non-small round cell soft tissue sarcoma (STS). We retrospectively reviewed 51 metastatic STS patients who were treated in Nagoya University Hospital from 2005 to 2015. The relation between various clinical factors and overall survival (OS) was analyzed. The log rank test and Cox’s proportional hazards test were used to evaluate the differences between groups. p-values of <0.05 were considered to indicate significance. The median follow-up period after first metastasis was 23.5 (1.6–97.1) months. There were 30 males and 21 females with a median age of 62 (15–88) years at first metastasis. The histologic subtypes were 17 undifferentiated pleomorphic sarcoma, 10 liposarcoma, 8 malignant peripheral nerve sheath tumor, and 16 others. Thirty patients had more than 2 metastases, and 15 patients had primary or local recurrent tumors. The metastatic sites were 31 lung only, 8 bone only, and 12 others. Twenty-two patients achieved DF status after surgeries and in one case proton radiotherapy for bone metastasis. DF status was marginally or significantly associated with good prognosis in patients with both pulmonary (p = 0.055) and extrapulmonary metastasis (p = 0.029). On multivariate analysis, DF status (p = 0.010) was an independent good prognostic factors for OS. In metastatic non-small round cell STS, it is an important treatment concept to achieve DF status whenever possible. This concept can apply both to pulmonary and extrapulmonary metastasis.
Literatur
2.
Zurück zum Zitat Ferguson PC et al (2011) Soft tissue sarcoma presenting with metastatic disease: outcome with primary surgical resection. Cancer 117(2):372–379CrossRefPubMed Ferguson PC et al (2011) Soft tissue sarcoma presenting with metastatic disease: outcome with primary surgical resection. Cancer 117(2):372–379CrossRefPubMed
3.
Zurück zum Zitat Billingsley KG et al (1999) Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg 229(5):602–610 discussion 10-2 CrossRefPubMedPubMedCentral Billingsley KG et al (1999) Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg 229(5):602–610 discussion 10-2 CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Blackmon SH et al (2009) Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg 88(3):877–884 discussion 84-5 CrossRefPubMed Blackmon SH et al (2009) Resection of pulmonary and extrapulmonary sarcomatous metastases is associated with long-term survival. Ann Thorac Surg 88(3):877–884 discussion 84-5 CrossRefPubMed
5.
Zurück zum Zitat Espat NJ et al (2002) Soft tissue sarcoma brain metastases. prevalence in a cohort of 3829 patients. Cancer 94(10):2706–2711CrossRefPubMed Espat NJ et al (2002) Soft tissue sarcoma brain metastases. prevalence in a cohort of 3829 patients. Cancer 94(10):2706–2711CrossRefPubMed
6.
Zurück zum Zitat Yoshikawa H et al (1998) Surgical treatment for skeletal metastases from soft tissue sarcomas: experience with 23 lesions in 20 patients. Sarcoma 2(2):107–114CrossRefPubMedPubMedCentral Yoshikawa H et al (1998) Surgical treatment for skeletal metastases from soft tissue sarcomas: experience with 23 lesions in 20 patients. Sarcoma 2(2):107–114CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Gronchi A et al (2010) Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg 251(3):506–511CrossRefPubMed Gronchi A et al (2010) Extremity soft tissue sarcoma in a series of patients treated at a single institution: local control directly impacts survival. Ann Surg 251(3):506–511CrossRefPubMed
8.
Zurück zum Zitat Weiser MR et al (2000) Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg 191(2):184–190 discussion 90-1 CrossRefPubMed Weiser MR et al (2000) Repeat resection of pulmonary metastases in patients with soft-tissue sarcoma. J Am Coll Surg 191(2):184–190 discussion 90-1 CrossRefPubMed
9.
Zurück zum Zitat Liebl LS et al (2007) Value of repeat resection for survival in pulmonary metastases from soft tissue sarcoma. Anticancer Res 27(4C):2897–2902PubMed Liebl LS et al (2007) Value of repeat resection for survival in pulmonary metastases from soft tissue sarcoma. Anticancer Res 27(4C):2897–2902PubMed
10.
Zurück zum Zitat Maki RG et al (2013) Toward better soft tissue sarcoma staging: building on american joint committee on cancer staging systems versions 6 and 7. Ann Surg Oncol 20(11):3377–3383CrossRefPubMedPubMedCentral Maki RG et al (2013) Toward better soft tissue sarcoma staging: building on american joint committee on cancer staging systems versions 6 and 7. Ann Surg Oncol 20(11):3377–3383CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Riad S et al (2004) Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res 426:129–134CrossRef Riad S et al (2004) Lymph node metastasis in soft tissue sarcoma in an extremity. Clin Orthop Relat Res 426:129–134CrossRef
12.
Zurück zum Zitat Sugahara S et al (2012) Carbon ion radiotherapy for localized primary sarcoma of the extremities: results of a phase I/II trial. Radiother Oncol 105(2):226–231CrossRefPubMed Sugahara S et al (2012) Carbon ion radiotherapy for localized primary sarcoma of the extremities: results of a phase I/II trial. Radiother Oncol 105(2):226–231CrossRefPubMed
14.
Zurück zum Zitat DeLaney TF et al (2014) Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol 110(2):115–122CrossRefPubMed DeLaney TF et al (2014) Long-term results of Phase II study of high dose photon/proton radiotherapy in the management of spine chordomas, chondrosarcomas, and other sarcomas. J Surg Oncol 110(2):115–122CrossRefPubMed
15.
Zurück zum Zitat Jiang L et al (2015) Significance of local treatment in patients with metastatic soft tissue sarcoma. Am J cancer Res 5(6):2075–2082PubMedPubMedCentral Jiang L et al (2015) Significance of local treatment in patients with metastatic soft tissue sarcoma. Am J cancer Res 5(6):2075–2082PubMedPubMedCentral
16.
Zurück zum Zitat Kepka L et al (2005) Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 63(3):852–859CrossRefPubMed Kepka L et al (2005) Results of radiation therapy for unresected soft-tissue sarcomas. Int J Radiat Oncol Biol Phys 63(3):852–859CrossRefPubMed
17.
Zurück zum Zitat Suri RM et al (2005) Pulmonary resection for metastatic malignant fibrous histiocytoma: an analysis of prognostic factors. Ann Thorac Surg 80(5):1847–1852CrossRefPubMed Suri RM et al (2005) Pulmonary resection for metastatic malignant fibrous histiocytoma: an analysis of prognostic factors. Ann Thorac Surg 80(5):1847–1852CrossRefPubMed
19.
Zurück zum Zitat Marudanayagam R et al (2011) Liver resection for metastatic soft tissue sarcoma: an analysis of prognostic factors. Eur J Surg Oncol 37(1):87–92CrossRefPubMed Marudanayagam R et al (2011) Liver resection for metastatic soft tissue sarcoma: an analysis of prognostic factors. Eur J Surg Oncol 37(1):87–92CrossRefPubMed
20.
Zurück zum Zitat Urakawa H et al (2015) Postoperative brain metastases in soft tissue sarcomas. Clin Exp Metastasis 32(4):345–351CrossRefPubMed Urakawa H et al (2015) Postoperative brain metastases in soft tissue sarcomas. Clin Exp Metastasis 32(4):345–351CrossRefPubMed
21.
Zurück zum Zitat Zagars GK et al (2003) Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 57(3):739–747CrossRefPubMed Zagars GK et al (2003) Prognostic factors for disease-specific survival after first relapse of soft-tissue sarcoma: analysis of 402 patients with disease relapse after initial conservative surgery and radiotherapy. Int J Radiat Oncol Biol Phys 57(3):739–747CrossRefPubMed
22.
Zurück zum Zitat Kim S et al (2011) Pulmonary resection of metastatic sarcoma: prognostic factors associated with improved outcomes. Ann Thorac Surg 92(5):1780–1786CrossRefPubMed Kim S et al (2011) Pulmonary resection of metastatic sarcoma: prognostic factors associated with improved outcomes. Ann Thorac Surg 92(5):1780–1786CrossRefPubMed
23.
Zurück zum Zitat Daigeler A et al (2009) Lymph node metastases in soft tissue sarcomas: a single center analysis of 1597 patients. Langenbeck’s archives of surgery/Deutsche Gesellschaft fur Chirurgie 394(2):321–329CrossRef Daigeler A et al (2009) Lymph node metastases in soft tissue sarcomas: a single center analysis of 1597 patients. Langenbeck’s archives of surgery/Deutsche Gesellschaft fur Chirurgie 394(2):321–329CrossRef
24.
Zurück zum Zitat Pervaiz N et al (2008) A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113(3):573–581CrossRefPubMed Pervaiz N et al (2008) A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113(3):573–581CrossRefPubMed
25.
Zurück zum Zitat Ueda T et al (1993) Aggressive pulmonary metastasectomy for soft tissue sarcomas. Cancer 72(6):1919–1925CrossRefPubMed Ueda T et al (1993) Aggressive pulmonary metastasectomy for soft tissue sarcomas. Cancer 72(6):1919–1925CrossRefPubMed
Metadaten
Titel
Impact of disease free status on prognosis in metastatic non-small round cell soft tissue sarcomas
verfasst von
Hiroshi Urakawa
Eiji Kozawa
Kunihiro Ikuta
Shunsuke Hamada
Naoki Ishiguro
Yoshihiro Nishida
Publikationsdatum
07.09.2016
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 8/2016
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-016-9820-z

Weitere Artikel der Ausgabe 8/2016

Clinical & Experimental Metastasis 8/2016 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.